Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.62 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 8/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9735956 | 0.79 | NOTUM (0.62) | NOTUMSRD5A1DAOMAT2AHSD17B10 | |
| SCHEMBL13279354 | 0.77 | NOTUM (0.39) | NOTUMSRD5A1DAOATMAHR | |
| SCHEMBL30615209 | 0.77 | NOTUM (1.00) | NOTUMDAOHTR2CHTR2A | |
| SCHEMBL9259627 | 0.77 | NOTUM (1.00) | NOTUMDAOHTR2CHTR2A | |
| SCHEMBL9736291 | 0.76 | NOTUM (0.57) | NOTUMSRD5A1DAOPLA2G10CYP1A2 | |
| SCHEMBL9264812 | 0.76 | NOTUM (0.57) | NOTUMCYP1A2CYP2A6HSD17B10HTR2C | |
| SCHEMBL9844699 | 0.72 | NOTUM (0.53) | NOTUMCYP1A2MAT2AHSD17B10 | |
| SCHEMBL28362608 | 0.68 | TFPI2 (0.35) | DAOPER2PLA2G10HSD17B10 | |
| SCHEMBL9287309 | 0.68 | NOTUM (0.51) | NOTUM | |
| SCHEMBL5775060 | 0.68 | NOTUM (0.44) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107973791-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 南京圣和药业股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-107614503-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 广东众生药业股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-12-13 | — | — | US | disclosed |
| EP-3290419-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-07 | — | — | EP | disclosed |
| EP-0441517-A2 | Tricyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | NOTUM 3245/4885SRD5A1 2569/4885DAO 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.